Health Trials

Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients

ConditionMultiple Myeloma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGruppo Italiano Malattie EMatologiche dell'Adulto

About this trial

This is an observational study aiming at collecting efficacy and safety data on the use of SVd outside clinical trials, for the treatment of adult patients with MM who have received 1-3 prior line of therapy.

A minimum of 159 patients is required. Overall study duration is estimated in 36 months.

Eligibility criteria

Qualifiers

Age equal to or greater than 18 years old at the time of SVd initiation

Signed informed consent (if applicable).

Diagnosis of symptomatic MM, as defined by the International Myeloma Working Group (IMWG) criteria.

Relapse after one to three lines of therapy.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

Gruppo Italiano Malattie EMatologiche dell'Adulto

Lead sponsor

Source ClinicalTrials.gov